WO2008150246A1 - Herbal haemostatic composition - Google Patents
Herbal haemostatic composition Download PDFInfo
- Publication number
- WO2008150246A1 WO2008150246A1 PCT/TR2007/000129 TR2007000129W WO2008150246A1 WO 2008150246 A1 WO2008150246 A1 WO 2008150246A1 TR 2007000129 W TR2007000129 W TR 2007000129W WO 2008150246 A1 WO2008150246 A1 WO 2008150246A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- haemostatic composition
- haemostatic
- composition according
- extracts
- bleeding
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/53—Lamiaceae or Labiatae (Mint family), e.g. thyme, rosemary or lavender
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/87—Vitaceae or Ampelidaceae (Vine or Grape family), e.g. wine grapes, muscadine or peppervine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
Definitions
- haemostatic products there are various haemostatic products to stop bleeding. When the haemostatic effectiveness of the products is weak, these products need to be changed frequently on the applied site of bleeding. These applications irritate the injured area, restart bleeding and cause pain. Therefore a strong haemostatic composition is needed.
- This invention due to its strong haemostatic effectiveness, stops or decreases bleeding in a very short time (less than 15 seconds) when applied to bleeding areas that has been injured or burned. It has been proved that, no cytotoxicity and sensitivity occurs at the applied area by the tests done using this composition.
- This invention describes a strong haemostatic composition that has been prepared by the extraction of herbal drugs from the identified parts of Urtica dioica, Vitis vinifera, Glycyrrhiza glabra, Alpinia officinarum and Thymus vulgaris which are suitable for pharmaceutical use.
- the invention describes the methods, devices and medical equipments that are used for applying this haemostatic composition to the wounds and/or burns or similar damages.
- the primary object of the invention is haemostatic compositions that has been prepared by the extraction of herbal drugs from the identified parts of Urtica dioica, Vitis vinifera, Glycyrrhiza glabra, Alpinia officinarum and Thymus vulgaris which are suitable for pharmaceutical use.
- haemostatic composition which may include pharmaceutical additives appropriate for the production of gel, cream, ointment, emulsion, suspension, aerosol, wound bandage, tampon etc forms that are intended for use to stop bleeding.
- Haemostatic composition of the invention can be prepared either by the water extraction of the herbal drugs of the identified parts of Urtica dioica, Vitis vinifera, Glycyrrhiza glabra, Alpinia officinarum and Thymus vulgaris all together at suitable proportions or by the water extraction of the herbal drugs of the identified parts of Urtica dioica, Vitis vinifera, Glycyrrhiza glabra, Alpinia officinarum and Thymus vulgaris separately and then combining the individual extracts at suitable proportions.
- compositions can be prepared by using the separate or combined alcohol extracts of the identified parts of Urtica dioica, Vitis vinifera, Glycyrrhiza glabra, Alpinia officinarum and Thymus vulgaris and/or dry materials obtained by drying the extracts of the same herbs and/or materials isolated from the same herbs and/or materials isolated from the same herbs being sold commercially.
- Urtica dioica the separate or combined alcohol extracts of the identified parts of Urtica dioica, Vitis vinifera, Glycyrrhiza glabra, Alpinia officinarum and Thymus vulgaris and/or dry materials obtained by drying the extracts of the same herbs and/or materials isolated from the same herbs and/or materials isolated from the same herbs being sold commercially.
- Above ground parts and roots of the herb can either be prepared fresh or dry or they can be found as extracts obtained in different ways as commercial product.
- Urtica dioica contains amines (i.e. histamine), formic acid, serotonins, flavonoids (i.e. quercitol and rutin), glycosides, tannins, carotenes and vitamin C in its structure.
- Urtica dioica is a herb type commonly used for urinary tract infections, rheumatic diseases, prostate adenomas and difficulty in urination.
- Above ground parts and roots of the herb can either be prepared fresh or dry or they can be found as extracts obtained in different ways as commercial product.
- Glycyrrhiza glabra contains glycyrrhizic acid and flavonoids (i.e. liquiritine and isoliquiritine) in its structure. Glycyrrhiza glabra has expectorant effect. Besides it is widely used for gastric and duodenal ulcers.
- Thymus vulgaris contains high amounts of phenolic compounds (thymole and carvacrole) in its structure. These compounds are strong antiseptics. Due to pulmonary discharge of them, they are used as respiratory tract antiseptic. Thymus vulgaris is used as respiratory tract antiseptic and anti-tussive in common cold diseases.
- phenolic compounds thymole and carvacrole
- Thymus vulgaris is used as respiratory tract antiseptic and anti-tussive in common cold diseases
- the herbs that are found in this haemostatic composition are also found in a variety of orally administered herbal drugs. Therefore although there is no concern about safety and it is well known that it has no toxicity on human, the haemostatic composition's safety has been proven with the tests shown below: Cytoxicity Test
- Haemostatic composition when evaluated on albino rabbits and guinea pigs according to international methods TS 5298 EN ISO 10993-1 (Biological evaluation of medical devices) and EN ISO 10993-10:2002 (Tests of cytotoxicity: in vitro methods) the composition was found no to have irritation and/or sensitivity effects.
- Haemostatic composition when evaluated according to international methods EN ISO 10993-1 (Biological evaluation of medical devices) and EN ISO 10993-4:1999 (Biological evaluation of medical devices: Selection of tests for interaction with blood) was shown to stop bleeding effectively, shorter than one second. It has been concluded that, haemostatic product can be used effectively in skin and mucosal bleedings.
- Haemostatic composition of the invention can be prepared either by the extraction of the herbal drugs of the identified parts of Urtica dioica, Vitis vinifera, Glycyrrhiza glabra, Alpinia off ⁇ cinarum and Thymus vulgaris all together at suitable proportions or by the extraction of the herbal drugs of the identified parts of Urtica dioica, Vitis vinifera, Glycyrrhiza glabra, Alpinia officinarum and Thymus vulgaris separately and then combining the individual extracts at suitable proportions.
- a sample composition that is prepared for direct applying, spraying or applying of impregnated dressing material to injured skin or mucosa is shown below:
- compositions of the invention can be prepared with different amounts, proportions and concentrations of drugs according to intended application and case.
- composition of the invention is used as haemostatic. This composition is used to control, decrease or stop the bleeding by applying to wounded areas, injured areas due to accidents and surgical operations, due to catheter application or dialysis needle insertion. Another application area for this composition is to control or decrease the damage due to dental or surgical operations or control or decrease the bleedings that accidentally occurs.
- Compositions, devices and applications of the invention can be used for dental bleedings, nasal bleedings, accidental bleedings due to minor cuts and cuts in haemophiliac patients (i.e. shaving cuts, minor cuts due to using personal hygienic tools, playing injuries, etc), wounds, circumcision wounds, surgical cuts and other minor cuts and injuries.
- Composition of the invention can also be applied to burns, necrotic and atrophic ulcers or wounds such as foot wounds seen in diabetic patients. It can stop bleeding and decrease the wound and damage in the injured area.
- Composition of the invention can include or can be used with epinephrine for some burns and wounds. Alternatively or additionally it can also be prepared or it can be used with using different antimicrobial and/or antiseptic agents. It can include chlorhexidine, furazidine, propolis, mexidole or a mixture thereof. For burns the ones that include hyaluronic acid, propolis and/or papaya are especially useful. For minor burns the materials that are prepared from non-cotton are appropriate. These dressing materials can include biocompatible polymers (hyaluronic acid and/or alginates) and a therapeutic agent.
- composition of the invention when used directly or with accessory devices was found to be effective in a variety of minor superficial bleedings.
- Haemostatic composition can be applied to bleeding site directly, as well as gently applying pressure on dressings by hand, elastic bandage, or plasters.
- haemostatic composition can stop bleeding shorter than 15 seconds time. It was shown that, in different trials using different haemostatic composition, accessory devices and applications, this time can be prolonged to 50 seconds depending on the severity of bleeding. In some cases haemostatic composition or the device can be left on the injured area for minutes, hours or days. In this case, it is recommended to replace the device including haemostatic composition few times.
- Haemostatic composition and devices also includes pharmaceutical formulations for topical and Trans dermal applications. For example by using haemostatic composition as an active ingredient with other contributory pharmaceutical compounds ointment, cream, paste, lotion, gel, powder, solution, spray or inhalants can be formulated.
- haemostatic composition can be used with devices or materials that make the haemostatic composition to diffuse to the injured area.
- Some of these application methods are; applying the product by using cotton or dressings made from other materials that are similar to cotton.
- Injured area can be covered by a dressing that is produced from appropriate material and impregnated with haemostatic composition or this area can be covered with elastic bandage impregnated with haemostatic composition.
- Haemostatic composition can be applied to injured area with dressings that are produced using all kind of suitable material. When needed dressings produced from air permeable material can be used or absorbent material can be used to eliminate fluid in the injured area.
- haemostatic material to the injured area
- dressings made from cotton or non- cotton material can be used.
- non-cotton dressing cellulose cellulose fibbers or viscon can be used.
- the products including haemostatic composition can be sterilized by irradiation (gamma irradiation) or ethylene oxide.
- Container that protects the sterile material from contamination can be covered using water resistant aluminium or plastic material.
- haemostatic composition can be formulated with biocompatible polymers and gels.
- Biocompatible polymers and gels will help coagulation by absorbing the fluid in the wound; thus increase the effectiveness of the product.
- These polymers are agar, agarose, carrageen, alginic acid and/or derivatives of alginic acid, hyaluronic acid and/or derivatives of hyaluronates, chitin, chitosan, fibrin, dextran and or dextran copolymers, polyvinylpyrrolidone, waxes, cellulose and/or derivatives of cellulose such as sodium carboxymethyl cellulose, ethyl cellulose and/or cellulose acetate, glycols such as propylene glycol or polyethylene glycol and the mixture of these.
- hydrophilic biopolymers can also be used.
- these can be hydrophilic diols, hydrophilic diamines or the combination of these.
- haemostatic composition can include hydro gel.
- hydro gel can be cross-linked keratin, polymethyl methacrylate, polyethylene glycol, ethylene/vinyl alcohol copolymer, polyalcoxy alkyl (meth)acrylate or the combination of these.
- Haemostatic composition when needed can include one or more pharmaceutical active ingredients.
- it can include an antimicrobial, an antibiotic, an antimycobacterial, an antifungal, an antiviral, and local anaesthetics such as lidocaine, procaine, tetracaine, dibucain, an analgesic, an antioxidant, an antiseptic, a vitamin or the combination of these .
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Biotechnology (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Microbiology (AREA)
- Medical Informatics (AREA)
- Botany (AREA)
- Alternative & Traditional Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
This is a haemostatic composition that is extracted from the specified parts of herbal drugs Urtica dioica, Vitis vinifera, Glycyrrhiza glabra, Alpinia officinarum and Thymus vulgaris and that can stop bleeding in a very short time.
Description
HERBAL HAEMOSTATIC COMPOSITION DESCRIPTION Background
There are various haemostatic products to stop bleeding. When the haemostatic effectiveness of the products is weak, these products need to be changed frequently on the applied site of bleeding. These applications irritate the injured area, restart bleeding and cause pain. Therefore a strong haemostatic composition is needed. This invention, due to its strong haemostatic effectiveness, stops or decreases bleeding in a very short time (less than 15 seconds) when applied to bleeding areas that has been injured or burned. It has been proved that, no cytotoxicity and sensitivity occurs at the applied area by the tests done using this composition.
Summary of Invention
This invention describes a strong haemostatic composition that has been prepared by the extraction of herbal drugs from the identified parts of Urtica dioica, Vitis vinifera, Glycyrrhiza glabra, Alpinia officinarum and Thymus vulgaris which are suitable for pharmaceutical use.
Additionally the invention describes the methods, devices and medical equipments that are used for applying this haemostatic composition to the wounds and/or burns or similar damages.
Detailed Description of Invention
The primary object of the invention is haemostatic compositions that has been prepared by the extraction of herbal drugs from the identified parts of Urtica dioica, Vitis vinifera, Glycyrrhiza glabra, Alpinia officinarum and Thymus vulgaris which are suitable for pharmaceutical use.
Alternatively, another object of the invention is the haemostatic composition which may include pharmaceutical additives appropriate for the production of gel, cream, ointment, emulsion, suspension, aerosol, wound bandage, tampon etc forms that are intended for use to stop bleeding.
Haemostatic composition of the invention can be prepared either by the water extraction of the herbal drugs of the identified parts of Urtica dioica, Vitis vinifera, Glycyrrhiza glabra, Alpinia officinarum and Thymus vulgaris all together at suitable proportions or by the water extraction of the herbal drugs of the identified parts of Urtica dioica, Vitis vinifera, Glycyrrhiza glabra, Alpinia officinarum and Thymus vulgaris separately and then combining the individual extracts at suitable proportions.
Alternatively, the compositions can be prepared by using the separate or combined alcohol extracts of the identified parts of Urtica dioica, Vitis vinifera, Glycyrrhiza glabra, Alpinia officinarum and Thymus vulgaris and/or dry materials obtained by drying the extracts of the same herbs and/or materials isolated from the same herbs and/or materials isolated from the same herbs being sold commercially.
Urtica dioica
Above ground parts and roots of the herb can either be prepared fresh or dry or they can be found as extracts obtained in different ways as commercial product.
Urtica dioica, contains amines (i.e. histamine), formic acid, serotonins, flavonoids (i.e. quercitol and rutin), glycosides, tannins, carotenes and vitamin C in its structure. Urtica dioica is a herb type commonly used for urinary tract infections, rheumatic diseases, prostate adenomas and difficulty in urination.
Vitis vinifera
Currently, fruits and seeds of the herb are very popular. It is commonly used in a lot of formulations which are applied orally or externally different purposes. It is used externally especially for healing of inflamed wounds. It is useful for supporting the weakened capillary vessels.
Glycyrrhiza glabra
Above ground parts and roots of the herb can either be prepared fresh or dry or they can be found as extracts obtained in different ways as commercial product.
Glycyrrhiza glabra contains glycyrrhizic acid and flavonoids (i.e. liquiritine and isoliquiritine) in its structure. Glycyrrhiza glabra has expectorant effect. Besides it is widely used for gastric and duodenal ulcers.
Alpina officinarum Above ground parts and roots of the herb which is also known as Kaempferia galanga can either be prepared fresh or dry or they can be found as extracts obtained in different ways as commercial product.
It is used for aphrodisiac effects in medium age human.
Thymus vulgaris
Above ground parts and roots of the herb can either be prepared fresh or dry or they can be found as extracts obtained in different ways as commercial product. Thymus vulgaris contains high amounts of phenolic compounds (thymole and carvacrole) in its structure. These compounds are strong antiseptics. Due to pulmonary discharge of them, they are used as respiratory tract antiseptic. Thymus vulgaris is used as respiratory tract antiseptic and anti-tussive in common cold diseases The herbs that are found in this haemostatic composition are also found in a variety of orally administered herbal drugs. Therefore although there is no concern about safety and it is well known that it has no toxicity on human, the haemostatic composition's safety has been proven with the tests shown below:
Cytoxicity Test
Haemostatic composition, when evaluated according to international methods TS 5298 EN ISO 10993-1 (Biological evaluation of medical devices) and EN ISO 10993-5:1999 (Tests of cytotoxicity: in vitro methods) was confirmed that, it has no cytotoxic effects.
Irritation and Sensitivity Test
Haemostatic composition when evaluated on albino rabbits and guinea pigs according to international methods TS 5298 EN ISO 10993-1 (Biological evaluation of medical devices) and EN ISO 10993-10:2002 (Tests of cytotoxicity: in vitro methods) the composition was found no to have irritation and/or sensitivity effects.
Haemostatic Effectiveness
Haemostatic composition, when evaluated according to international methods EN ISO 10993-1 (Biological evaluation of medical devices) and EN ISO 10993-4:1999 (Biological evaluation of medical devices: Selection of tests for interaction with blood) was shown to stop bleeding effectively, shorter than one second. It has been concluded that, haemostatic product can be used effectively in skin and mucosal bleedings.
Preparation Method of Haemostatic Composition
Haemostatic composition of the invention can be prepared either by the extraction of the herbal drugs of the identified parts of Urtica dioica, Vitis vinifera, Glycyrrhiza glabra, Alpinia offϊcinarum and Thymus vulgaris all together at suitable proportions or by the extraction of the herbal drugs of the identified parts of Urtica dioica, Vitis vinifera, Glycyrrhiza glabra, Alpinia officinarum and Thymus vulgaris separately and then combining the individual extracts at suitable proportions.
A sample composition that is prepared for direct applying, spraying or applying of impregnated dressing material to injured skin or mucosa is shown below:
Amount (mg/100 ml) Urtica dioica 6.0
Vitis vinifera 8.0
Glycyrrhiza glabra 7.0
Alpinia officinarum 7.0
Thymus vulgaris 5.0
The amounts given above are sample figures only and the invention is not limited to these amounts. Compositions of the invention can be prepared with different amounts, proportions and concentrations of drugs according to intended application and case.
The areas that Haemostatic composition of the invention can be used
The composition of the invention is used as haemostatic. This composition is used to control, decrease or stop the bleeding by applying to wounded areas, injured areas due to accidents and surgical operations, due to catheter application or dialysis needle insertion.
Another application area for this composition is to control or decrease the damage due to dental or surgical operations or control or decrease the bleedings that accidentally occurs. Compositions, devices and applications of the invention can be used for dental bleedings, nasal bleedings, accidental bleedings due to minor cuts and cuts in haemophiliac patients (i.e. shaving cuts, minor cuts due to using personal hygienic tools, playing injuries, etc), wounds, circumcision wounds, surgical cuts and other minor cuts and injuries.
Composition of the invention can also be applied to burns, necrotic and atrophic ulcers or wounds such as foot wounds seen in diabetic patients. It can stop bleeding and decrease the wound and damage in the injured area. Composition of the invention can include or can be used with epinephrine for some burns and wounds. Alternatively or additionally it can also be prepared or it can be used with using different antimicrobial and/or antiseptic agents. It can include chlorhexidine, furazidine, propolis, mexidole or a mixture thereof. For burns the ones that include hyaluronic acid, propolis and/or papaya are especially useful. For minor burns the materials that are prepared from non-cotton are appropriate. These dressing materials can include biocompatible polymers (hyaluronic acid and/or alginates) and a therapeutic agent.
Composition of the invention when used directly or with accessory devices was found to be effective in a variety of minor superficial bleedings. Haemostatic composition can be applied to bleeding site directly, as well as gently applying pressure on dressings by hand, elastic bandage, or plasters.
Clinical trials using haemostatic composition shown that, the product can stop bleeding shorter than 15 seconds time. It was shown that, in different trials using different haemostatic composition, accessory devices and applications, this time can be prolonged to 50 seconds depending on the severity of bleeding. In some cases haemostatic composition or the device can be left on the injured area for minutes, hours or days. In this case, it is recommended to replace the device including haemostatic composition few times.
Haemostatic composition and devices also includes pharmaceutical formulations for topical and Trans dermal applications. For example by using haemostatic composition as an active ingredient with other contributory pharmaceutical compounds ointment, cream, paste, lotion, gel, powder, solution, spray or inhalants can be formulated.
Alternatively or in addition to this it can be used with devices or materials that make the haemostatic composition to diffuse to the injured area. Some of these application methods are; applying the product by using cotton or dressings made from other materials that are similar to cotton. Injured area can be covered by a dressing that is produced from appropriate material and impregnated with haemostatic composition or this area can be covered with elastic bandage impregnated with haemostatic composition. Haemostatic composition can be applied to injured area with dressings that are produced using all kind of suitable material. When needed dressings produced from air permeable material can be used or absorbent material can be used to eliminate fluid in the injured area.
To apply haemostatic material to the injured area, dressings made from cotton or non- cotton material can be used. To produce non-cotton dressing cellulose, cellulose fibbers or viscon can be used.
When needed the products including haemostatic composition can be sterilized by irradiation (gamma irradiation) or ethylene oxide. Container that protects the sterile material from contamination can be covered using water resistant aluminium or plastic material.
Biocompatible Polymers and Gels
Alternatively haemostatic composition can be formulated with biocompatible polymers and gels. Biocompatible polymers and gels will help coagulation by absorbing the fluid in the wound; thus increase the effectiveness of the product.
These polymers are agar, agarose, carrageen, alginic acid and/or derivatives of alginic acid, hyaluronic acid and/or derivatives of hyaluronates, chitin, chitosan, fibrin, dextran and or dextran copolymers, polyvinylpyrrolidone, waxes, cellulose and/or derivatives of cellulose such as sodium carboxymethyl cellulose, ethyl cellulose and/or cellulose acetate, glycols such as propylene glycol or polyethylene glycol and the mixture of these.
In some cases hydrophilic biopolymers can also be used. For example these can be hydrophilic diols, hydrophilic diamines or the combination of these.
In some cases haemostatic composition can include hydro gel. For example these can be cross-linked keratin, polymethyl methacrylate, polyethylene glycol, ethylene/vinyl alcohol copolymer, polyalcoxy alkyl (meth)acrylate or the combination of these.
Pharmaceutical Agents
Haemostatic composition when needed can include one or more pharmaceutical active ingredients. For example it can include an antimicrobial, an antibiotic, an antimycobacterial, an antifungal, an antiviral, and local anaesthetics such as lidocaine, procaine, tetracaine, dibucain, an analgesic, an antioxidant, an antiseptic, a vitamin or the combination of these .
Claims
1. A haemostatic composition comprising extracts of herbal drugs of Urtica dioica, Vitis vinifera, Glycyrrhiza glabra, Alpinia offϊcinarum and Thymus vulgaris.
2. Haemostatic composition according to claim 1 wherein the extracts of herbal drugs are extracted together.
3. Haemostatic composition according to claim 1 wherein the extracts of herbal drugs are extracted separately and the haemostatic composition is prepared by combining fluids of these individually extracted herbal drugs and/or the dry extracts which are produced by evaporating the liquid part of the extracts and/or compounds that are isolated from these drugs.
4. Haemostatic composition according to any of the preceding claims wherein the extraction is made by water or alcohol
5. Haemostatic composition according to any of the preceding claims wherein the composition contains one or more additional therapeutic agents.
6. Haemostatic composition according to claim 5 wherein the additional therapeutic agent is selected from one or more of antimicrobial, antibiotic, antimycobacterial, antifungal, antiviral, antiseptic, antineoplastic, immune system reaction modifier, antithrombotic, spasmolytic, antiulcer, skeletal muscle or smooth muscle spasmolytic, antihistaminic, local anaesthetic, analgesic, narcotic antagonist, nonsteroidal anti-inflammatory agent, steroidal anti-inflammatory agent, antioxidant, vaso-active agent or vitamin.
7. Haemostatic composition according to any of the preceding claims is impregnated to or applied to one side of a suitable dressing for topical or transdermal use.
8. Haemostatic composition according to any of the preceding claims wherein the composition contains one or more biocompatible polymers or gels.
9. Haemostatic composition according to any of the preceding claims is used for to stop bleeding or decrease the severity of bleeding or controlling the bleeding.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| TR2007/03933 | 2007-06-07 | ||
| TR200703933 | 2007-06-07 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| WO2008150246A1 true WO2008150246A1 (en) | 2008-12-11 |
Family
ID=38969381
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PCT/TR2007/000129 Ceased WO2008150246A1 (en) | 2007-06-07 | 2007-11-06 | Herbal haemostatic composition |
Country Status (1)
| Country | Link |
|---|---|
| WO (1) | WO2008150246A1 (en) |
Cited By (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101889953A (en) * | 2010-07-29 | 2010-11-24 | 李国钧 | Device and method for manufacturing drug smoke liquid and drug smoke |
| US8623842B2 (en) | 2006-09-27 | 2014-01-07 | Hemostasis, Llc | Hemostatic agent and method |
| US9061087B2 (en) | 2008-03-04 | 2015-06-23 | Hemostasis, Llc | Method of making a hemostatic sponge wound dressing comprising subjecting the sponge to water vapor |
| CN106236811A (en) * | 2015-06-11 | 2016-12-21 | 黑龙江康普生物科技有限公司 | The waterproof liquid film of disinfecting hemostasis pain relieving and preparation method |
| IT201600070397A1 (en) * | 2016-07-06 | 2018-01-06 | Lifecode Supplements Di Marcelli Valerio | COMPOSITION BASED ON GREEN LEAF PLANTS TO INCREASE THE BODY LEVELS OF NITRIC OXIDE |
Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RO83870A2 (en) * | 1982-05-17 | 1984-04-12 | Intreprinderea De Produse Cosmetice "Nivea",Ro | HYTOTAPEUTIC PREPARE FOR THE TREATMENT OF ALVEOLITE POSTE0TRACTION |
| EP0341795A1 (en) * | 1988-05-09 | 1989-11-15 | Rodriso Holding B.V. | Mouthcare-products |
| RO103501A2 (en) * | 1989-01-18 | 1991-12-02 | Plafar Cluj Napoca | Medicinal mouth water concentrate |
| JP2004210757A (en) * | 2003-01-07 | 2004-07-29 | Kenji Omura | Tooth brush soldier produced by mixing tooth paste with salt and liquid squeezed from ginger |
| WO2006067549A1 (en) * | 2004-12-20 | 2006-06-29 | Koletex, Limited Liability Company | Hemostatic composition, apparatus, and methods |
-
2007
- 2007-11-06 WO PCT/TR2007/000129 patent/WO2008150246A1/en not_active Ceased
Patent Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RO83870A2 (en) * | 1982-05-17 | 1984-04-12 | Intreprinderea De Produse Cosmetice "Nivea",Ro | HYTOTAPEUTIC PREPARE FOR THE TREATMENT OF ALVEOLITE POSTE0TRACTION |
| EP0341795A1 (en) * | 1988-05-09 | 1989-11-15 | Rodriso Holding B.V. | Mouthcare-products |
| RO103501A2 (en) * | 1989-01-18 | 1991-12-02 | Plafar Cluj Napoca | Medicinal mouth water concentrate |
| JP2004210757A (en) * | 2003-01-07 | 2004-07-29 | Kenji Omura | Tooth brush soldier produced by mixing tooth paste with salt and liquid squeezed from ginger |
| WO2006067549A1 (en) * | 2004-12-20 | 2006-06-29 | Koletex, Limited Liability Company | Hemostatic composition, apparatus, and methods |
Non-Patent Citations (4)
| Title |
|---|
| DATABASE WPI Week 198438, Derwent World Patents Index; AN 1984-235461, XP002466824 * |
| DATABASE WPI Week 199325, Derwent World Patents Index; AN 1993-203503, XP002466823 * |
| DATABASE WPI Week 200452, Derwent World Patents Index; AN 2004-538855, XP002467362 * |
| DATABASE XPTK NISCAIR New Delhi India; 1999, "Draksadiyogah", XP018003691 * |
Cited By (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8623842B2 (en) | 2006-09-27 | 2014-01-07 | Hemostasis, Llc | Hemostatic agent and method |
| US9649482B2 (en) | 2006-09-27 | 2017-05-16 | Hemostasis, Llc | Hemostatic agent and method |
| US10744310B2 (en) | 2006-09-27 | 2020-08-18 | Hemostasis, Llc | Hemostatic agent and method |
| US9061087B2 (en) | 2008-03-04 | 2015-06-23 | Hemostasis, Llc | Method of making a hemostatic sponge wound dressing comprising subjecting the sponge to water vapor |
| CN101889953A (en) * | 2010-07-29 | 2010-11-24 | 李国钧 | Device and method for manufacturing drug smoke liquid and drug smoke |
| CN101889953B (en) * | 2010-07-29 | 2013-05-29 | 李国钧 | Device and method for manufacturing drug smoke liquid and drug smoke |
| CN106236811A (en) * | 2015-06-11 | 2016-12-21 | 黑龙江康普生物科技有限公司 | The waterproof liquid film of disinfecting hemostasis pain relieving and preparation method |
| IT201600070397A1 (en) * | 2016-07-06 | 2018-01-06 | Lifecode Supplements Di Marcelli Valerio | COMPOSITION BASED ON GREEN LEAF PLANTS TO INCREASE THE BODY LEVELS OF NITRIC OXIDE |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Khorasani et al. | Aloe versus silver sulfadiazine creams for second-degree burns: a randomized controlled study | |
| Davis et al. | Wound healing. Oral and topical activity of Aloe vera | |
| US20060105000A1 (en) | Compositions for treating infected skin and mucous membrane comprising an anti-microbial agent and an essential oil | |
| US9011901B2 (en) | Method of promoting hemostasis by using a dressing comprising extract of chamomile and nettle | |
| RU2571063C2 (en) | Polysaccharide of tamarind seed for application in treatment of microbial infections | |
| CA2899661A1 (en) | Compositions and methods for treating surface wounds | |
| US12290599B2 (en) | Oil-based wound care compositions and methods | |
| WO2010062581A2 (en) | A botanical composition for enhanced skin repair and uses thereof | |
| AU2007231781B2 (en) | Method and device for treating bursitis | |
| ES3038299T3 (en) | Dermal skin protectant and carrier | |
| Jacobsen | Topical wound treatments and wound‐care products | |
| CN102917719B (en) | Kit of medicines for treating and/or preventing skin ulcers | |
| WO2008150246A1 (en) | Herbal haemostatic composition | |
| RU2128990C1 (en) | Anti-inflammatory and wound-healing ointment "vundehil" | |
| RU2188016C1 (en) | Adhesive curative-prophylactic composition | |
| US8900601B2 (en) | Permeable mixtures, methods and compositions for the skin | |
| KR102445058B1 (en) | Roll-type ointment with improved usability and hygiene | |
| US8173183B2 (en) | Mucosal membrane healant and moisturizer | |
| GR20210100036A (en) | Pharmaceutical and/or cosmetic formulation comprising natural ingredients | |
| WO2024049361A1 (en) | Mixtures of cannabinoid-based compositions and active substances from other genera for medical applications and associates | |
| Gopinathan et al. | Effect of Calendula officinalis in burn wounds of bovine calves and heifers | |
| KR20220144070A (en) | Burn treatment composition containing egg shell powder as an active ingredient | |
| CN117064987A (en) | A pharmaceutical composition for treating traumatology, and its preparation method and application | |
| KR20010007724A (en) | The band with an anesthesia effect and sterilization | |
| WO2020044368A1 (en) | Wakeri for wound healing |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| DPE2 | Request for preliminary examination filed before expiration of 19th month from priority date (pct application filed from 20040101) | ||
| 121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 07835629 Country of ref document: EP Kind code of ref document: A1 |
|
| NENP | Non-entry into the national phase |
Ref country code: DE |
|
| 122 | Ep: pct application non-entry in european phase |
Ref document number: 07835629 Country of ref document: EP Kind code of ref document: A1 |